A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
AMAZE 5
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)
3 other identifiers
interventional
400
10 countries
82
Brief Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 obesity
Started Apr 2026
Typical duration for phase_3 obesity
82 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 13, 2026
CompletedFirst Posted
Study publicly available on registry
March 19, 2026
CompletedStudy Start
First participant enrolled
April 13, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 14, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 14, 2028
May 14, 2026
May 1, 2026
2.3 years
March 13, 2026
May 13, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Relative change in body weight
Measured as percentage (%) of body weight.
From baseline (week 0) to (week 80)
Change in WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) pain score
Measured as score on a scale. Western Ontario and McMaster Universities Arthritis Index (WOMAC) measures symptoms in the areas of pain, stiffness, and physical function. The measure consists of 24 items yielding 3 subscale scores and 1 total score. WOMAC raw scores are transformed to a standardised 0 to 100 score range. Higher scores indicate worse pain, stiffness, physical function, and overall osteoarthritis- related disability.
From baseline (week 0) to (week 80)
Secondary Outcomes (27)
Change in WOMAC physical function score
From baseline (week 0) to (week 80)
Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score
From baseline (week 0) to (week 80)
Change in body weight
From baseline (week 0) to (week 80)
Change in body mass index (BMI)
From baseline (week 0) to (week 80)
Change in WOMAC stiffness score
From baseline (week 0) to (week 80)
- +22 more secondary outcomes
Study Arms (3)
NNC0487-0111 dose level 1
EXPERIMENTALParticipants will be randomized to receive NNC0487-0111 dose level 1 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
NNC0487-0111 dose level 2
EXPERIMENTALParticipants will be randomized to receive NNC0487-0111 dose level 2 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Placebo
PLACEBO COMPARATORParticipants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Interventions
NNC0487-0111 dose level 1 and dose level 2 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Eligibility Criteria
You may qualify if:
- Male or female (sex at birth).
- Age 18 years or above at the time of signing the informed consent.
- Clinical diagnosis of knee osteoarthritis (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence (KL) grades 2 to 3 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg.
- Symptomatic knee OA with first appearance of pain in the target knee more than (\>) 90 days prior to screening and pain in the target knee for \> 15 days over the prior 30 days.
- Willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 gram (g)/day is allowed as rescue medication up until 24 hours before those visits).
You may not qualify if:
- Glycated haemoglobin more than or equal to (≥) 6.5% \[(48 millimoles per mole (mmol/mol)\] as measured by the central laboratory at screening.
- History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
- Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.
- Any joint prosthesis or joint replacement in target knee.
- Arthroscopy or injections into target knee within the last 90 days prior to screening.
- Any other joint disease in target knee including gout and pseudogout.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Novo Nordisk A/Slead
Study Sites (82)
Arizona Research Center, Inc.
Phoenix, Arizona, 85053, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598, United States
Chase Medical Research LLC
Hamden, Connecticut, 06517, United States
Chase Medical Research LLC
Waterbury, Connecticut, 06708, United States
Zenith clinical research
Hollywood, Florida, 33021, United States
CNS Healthcare
Jacksonville, Florida, 32256, United States
Angels Clinical Research Institute
Miami Lakes, Florida, 33016, United States
Hope Clin Res & Wellness
Conyers, Georgia, 30094, United States
CenExel iResearch, LLC
Decatur, Georgia, 30030, United States
Elite Clinical Trials
Blackfoot, Idaho, 83221, United States
MedVadis Research Watertown
Waltham, Massachusetts, 02451, United States
Jubilee Clinical Research, Inc.
Las Vegas, Nevada, 89106, United States
Great Lakes Medical Research
Westfield, New York, 14787, United States
Accellacare and KDCILM, LLC
Wilmington, North Carolina, 28401, United States
Coastal Carolina Res Ctr
North Charleston, South Carolina, 29405, United States
VIP Trials_San Antonio
San Antonio, Texas, 78230, United States
Charlottesville Med Research
Charlottesville, Virginia, 22911, United States
Health Res of Hampton Roads
Newport News, Virginia, 23606, United States
Northwest Clinical Research Center
Bellevue, Washington, 98007, United States
Emeritus Research Sydney
Botany, New South Wales, 2019, Australia
Momentum Clinical Research Darlinghurst
Darlinghurst, New South Wales, 2010, Australia
Kolling Institute
St Leonards, New South Wales, 2065, Australia
Heart of Australia
Chelmer, Queensland, 4068, Australia
Coastal Digestive Health
Maroochydore, Queensland, 4558, Australia
UMHAT Sveti Georgi EAD, Plovdiv
Plovdiv, 4002, Bulgaria
MC Dr. Atanasov EOOD
Sofia, 1231, Bulgaria
MC Excelsior OOD
Sofia, 1407, Bulgaria
UMHAT Tsaritsa Yoanna - ISUL EAD, Orthopaedics and Traumatology
Sofia, 1527, Bulgaria
MMA MHAT - Sofia, Rheumatology clinic
Sofia, 1606, Bulgaria
UMHAT Sveti Ivan Rilski EAD, Rheumatology
Sofia, 1612, Bulgaria
Laser Rejuvenation Clinics Inc.
Calgary, Alberta, T2W 4X9, Canada
Dawson Clinical Research
Guelph, Ontario, N1H 1B1, Canada
Hamilton Medical Rsrch Grp
Hamilton, Ontario, L8L 5G4, Canada
Centre de Recherche Musculo
Trois-Rivières, Quebec, G8Z 1Y2, Canada
Alpha Recherche Clinique - Lebourgneuf
Québec, G2J OC4, Canada
Aarhus Universitetshospital - Klinik for Led og bindevævssygdomme
Aarhus N, 8200, Denmark
Frederiksberg Hospital - Parker Institutet (Artrose)
Frederiksberg, 2000, Denmark
Sanos Clinic - Herlev
Herlev, 2730, Denmark
University General Hospital Attikon General Hospital Of West Attica H Agia Varvara - 2nd dept of Internal medicine
Chaïdári, Attica, 12461, Greece
Laiko General Hospital Of Athens - 1st department of Internal Medicine
Athens, 115 27, Greece
Athens Medical Center S.A. (Iatriko Psychicou) - Department of Internal Medicine & Metabolic Diseases
Athens, 11525, Greece
General Hospital Of Athens Alexandra - Clinical Therapeutics
Athens, 11528, Greece
Athens Medical Center S.A. (Iatriko Athinon) - Diabetes and Obesity Unit
Marousi, 15125, Greece
NextHealth S.A. - Department of Endocrinology, Metabolism & Diabetes
Thessaloniki, 54635, Greece
Thermi Clinic S.A. - Diabetes and Internal Medicine Department
Thessaloniki, 57001, Greece
AOU Federico II Di Napoli - DAI Endocr. Diab. Andro. e Nutr. - UOC Medicina Interna e Nutrizione Clinica
Naples, Campania, 80131, Italy
Ospedale Civile di Baggiovara - UOC Endocrinologia
Modena, Emilia-Romagna, 41126, Italy
Ospedale S. Maria della Misericordia - Reparto Endocrinologia e Malattie del Metabolismo
Udine, Friuli Venezia Giulia, 33100, Italy
Pol. Uni. Campus Biomedico - UOC Endocrinologia e Diabetologia
Rome, Lazio, 00128, Italy
Auxologico San Luca - Endocrinologia e Malattie del Metabolismo
Milan, Lombardy, 20149, Italy
Policlinico San Donato di Milano S.p.A - UOS Endocrinologia e del Servizio di Nutrizione Clinica e Prevenzione Cardiometabolica
San Donato Milanese, Lombardy, 20097, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Civile Maggiore Borgo Trento - U.O. Reumatologia
Verona, Veneto, 37126, Italy
"Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
Bialystok, Podlaskie Voivodeship, 15-351, Poland
"Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
Bialystok, Podlaskie Voivodeship, 15-351, Poland
ClinicMed Daniluk, Nowak Spółka Komandytowa
Bialystok, 15-879, Poland
ClinicMed Daniluk, Nowak Spółka Komandytowa
Bialystok, 15-879, Poland
Centrum Medyczne Intercor Sp. z o.o.
Bydgoszcz, 85-605, Poland
Centrum Medyczne Intercor Sp. z o.o.
Bydgoszcz, 85-605, Poland
CenterMed Kraków Sp. z o.o.
Krakow, 31-530, Poland
CenterMed Kraków Sp. z o.o.
Krakow, 31-530, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o.
Krakow, 31-826, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o.
Krakow, 31-826, Poland
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher
Warsaw, 02-637, Poland
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher
Warsaw, 02-637, Poland
Instituto Medico Quirurgico San Rafael
A Coruña, 15006, Spain
Hospital Germans Trias i Pujol
Badalona, 08916, Spain
Hospital Naval Ferrol
Ferrol, 15405, Spain
Centro Especialidades Hermanos Sangro
Madrid, 28038, Spain
Hospital Quirónsalud Málaga
Málaga, 29004, Spain
Hospital Infanta Sofía
San Sebastián de Los Reyes (Madrid), 28702, Spain
Hospital Universitario Marqués de Valdecilla
Santander, 39008, Spain
Hospital HM La Esperanza
Santiago de Compostela, 15705, Spain
Clínica Nuevas Tecnologías en Diabetes y Endocrinología
Seville, 41003, Spain
H. Infanta Luisa_Endocrino y Obesidad
Seville, 41010, Spain
Hospital General de Valencia
Valencia, 46014, Spain
Ankara Üniversitesi Sağlık Uygulama ve Araştırma Hastaneleri- Fiziksel Tıp ve Rehabilitasyon
Altındağ/Ankara, 06230, Turkey (Türkiye)
İstanbul Fizik Tedavi ve Rehabilitasyon Eğitim ve Araştırma Hastanesi
Bahçelievler/İstanbul, 34186, Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi- Fizik Tedavi ve Rehabilitasyon
Çankaya/Ankara, 06800, Turkey (Türkiye)
Çanakkale Onsekiz Mart Üniversitesi Sağlık Araştırma ve Uygulama Hastanesi-Fiziksel Tıp ve Rehabilitasyon
Kepez/Çanakkale Merkez/Çanakkale, 17110, Turkey (Türkiye)
İnönü Üniversitesi Turgut Özal Tıp Merkezi Hastanesi-Fiziksel Tıp ve Rehabilitasyon
Merkez/Battalgazi/Malatya, 44280, Turkey (Türkiye)
Karadeniz Teknik Üniversitesi Farabi Hastanesi- Fiziksel Tıp ve Rehabilitasyon
Trabzon Merkez/Ortahisar/Trabzon, 61080, Turkey (Türkiye)
Adana Şehir Eğitim ve Araştırma Hastanesi-Fizik Tedavi ve Rehabilitasyon
Yuregir/Adana, 01060, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Transparency (dept. 2834)
Novo Nordisk A/S
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 13, 2026
First Posted
March 19, 2026
Study Start
April 13, 2026
Primary Completion (Estimated)
August 14, 2028
Study Completion (Estimated)
August 14, 2028
Last Updated
May 14, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will share
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com